[Corrigendum] miR‑505 suppresses prostate cancer progression by targeting NRCAM

• Authors:
  • Xiao‑Hui Ling
  • Hao Fu
  • Zhi‑Yun Chen
  • Jian‑Ming Lu
  • Yang‑Jia Zhuo
  • Jia‑Hong Chen
  • Wei‑De Zhong
  • Zhenyu Jia

• View Affiliations

  
  Affiliations: Guangdong Provincial Institute of Nephrology, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China, Department of Urology, Nanhua Affiliated Hospital, University of South China, Hengyang, Hunan 421001, P.R. China, Reproductive Medicine Centre, Huizhou Central People's Hospital, Guangdong Medical University, Huizhou, Guangdong 516001, P.R. China, Department of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510180, P.R. China, Department of Botany and Plant Sciences, University of California, Riverside, CA 92521, USA
• Published online on: July 17, 2020     https://doi.org/10.3892/or.2020.7696
• Pages: 1771-1771

• Copyright : © Ling et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Article